Clinical Trials Moving Forward
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
You may also be interested in...
FDA Developing Guidance On Rational Development Of Combined Novel Drugs
FDA is developing guidances -both in general and for specific therapeutic areas - for co-development of investigational drugs intended to be used in combination, and the move is indeed timely.
Taking Aim At Recurrence: Targeting Cancer Stem Cells To Stop Proliferation
An emerging field of oncology drug development offers the potential for eradicating all remaining cancer cells following treatment – and thus preventing recurrence – by targeting the so-called cancer stem cells that are thought to be involved in cancer proliferation, treatment resistance, and metastasis.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011